US Supreme Court to Hear Pay-for-Delay Case - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

US Supreme Court to Hear Pay-for-Delay Case


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Supreme Court agreed on Friday, Dec. 7, 2012, to hear a case that will decide whether brand-name drug companies may pay generic drug companies to delay introduction of lower-cost generic drugs. At the request of the Federal Trade Commission (FTC), the US Solicitor General petitioned the Supreme Court to review a federal appeals court ruling that upheld a “pay-for-delay” arrangement between Solvay Pharmaceuticals, now owned by Abbott Laboratories, and generic-drug makers, such as Watson Pharmaceuticals, Paddock Laboratories, and Par Pharmaceutical. A decision on the case of Federal Trade Commission v. Watson Pharmaceuticals Inc. et al. (No. 12-416) is expected by the end of June 2013.

The FTC filed a complaint in 2009 alleging that the companies violated antitrust laws when Solvay paid the generic firms in exchange for their agreement to abandon patent challenges and refrain from marketing a generic version of AndroGel until 2015, noted the FTC in an Oct. 4, 2012 press release. A district court dismissed the FTC complaint, and, in April 2012, the 11th US Circuit Court of Appeals also ruled against the FTC and upheld the arrangement.

Drug companies say the settlements, also known as reverse payments, are a legitimate way to settle patent disputes. The FTC, however, says that the arrangements hurt American consumers. Other court cases over the last several years have dealt with the pay-for-delay practice, and the Supreme Court ruling is anticipated to set a national standard.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here